IPO Update: 35 Biopharmas Provide -6.1% Average Return; New Offerings Feel Stock Market Impact

 
• By Mandy Jackson

Only 16 drug developers that went public in the US during the first three quarters are trading in positive territory. While the IPO queue keeps growing, ADC Therapeutics and Monopar cite "market conditions" as they postpone their offerings.

IPO Initial Private Offering Stock Market Ticker Building 3d Illustration
35 biopharma companies raised $4.5bn, but 19 gave IPO investors a loss. • Source: Shutterstock

More from Financing

More from Business